The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study

Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2006-08, Vol.15 (8), p.1520-1525
Hauptverfasser: BERWICK, Marianne, ORLOW, Irene, GALLAGHER, Richard P, DWYER, Terence, REBBECK, Timothy R, KANETSKY, Peter A, BUSAM, Klaus, FROM, Lynn, MUJUMDAR, Urvi, WILCOX, Homer, BEGG, Colin B, HUMMER, Amanda J, ARMSTRONG, Bruce K, KRICKER, Anne, MARRETT, Loraine D, MILLIKAN, Robert C, GRUBER, Stephen B, ANTON-CULVER, Hoda, ZANETTI, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1525
container_issue 8
container_start_page 1520
container_title Cancer epidemiology, biomarkers & prevention
container_volume 15
creator BERWICK, Marianne
ORLOW, Irene
GALLAGHER, Richard P
DWYER, Terence
REBBECK, Timothy R
KANETSKY, Peter A
BUSAM, Klaus
FROM, Lynn
MUJUMDAR, Urvi
WILCOX, Homer
BEGG, Colin B
HUMMER, Amanda J
ARMSTRONG, Bruce K
KRICKER, Anne
MARRETT, Loraine D
MILLIKAN, Robert C
GRUBER, Stephen B
ANTON-CULVER, Hoda
ZANETTI, Roberto
description Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)
doi_str_mv 10.1158/1055-9965.EPI-06-0270
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68718627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68718627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</originalsourceid><addsrcrecordid>eNpFkcFy0zAQhjUMDC2FR4DRBYaLy8q2LJlbCKVkSCBTylmzkdaNwZaDZJfpG_DYKE2YnnZ39O0v6f8ZeyngXAip3wmQMqvrSp5frBcZVBnkCh6xUyELnSkl5ePU_2dO2LMYfwKAqqV8yk5EpesKyuKU_b3eEl8HusWOvCU-NHz-8cvXfMYvKfTZsvXEV9OIYzv4yNE7fkVdmm6JX7XxF2-GwOfp3NMwRb7Crr3x6Ee-SpQfenzPZ54v_EjB32tgx9fDburuh-wDRnL8-zi5u-fsSYNdpBfHesZ-fLq4nn_Olt8uF_PZMrOlUGOmN0o1KBxUjdCVa5wmSyWopiDlNqpEsjovsCgdAFpRC-1yh7pUBHmdCyjO2JuD7i4MvyeKo-nbaKnrDl8wlVZJOFcJlAfQhiHGQI3ZhbbHcGcEmH0EZm-v2dtrUgQGKrOPIO29Ol4wbXpyD1tHzxPw-ghgtNg1Ab1t4wOnoajqUibu7YHbtjfbP20gYxNJIVAkDHZrhDTpETKH4h_DSJ4O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68718627</pqid></control><display><type>article</type><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto</creator><creatorcontrib>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto ; GEM Study Group ; The GEM Study Group</creatorcontrib><description>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-06-0270</identifier><identifier>PMID: 16896043</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Australia - epidemiology ; Biological and medical sciences ; Canada - epidemiology ; Case-Control Studies ; Chromatography, High Pressure Liquid ; Cyclin-Dependent Kinase Inhibitor p16 - genetics ; Dermatology ; Exons - genetics ; Female ; Germ-Line Mutation ; Humans ; International Agencies ; Introns - genetics ; Italy - epidemiology ; Male ; Medical sciences ; Melanoma ; Melanoma - epidemiology ; Melanoma - genetics ; Middle Aged ; Neoplasms, Multiple Primary - epidemiology ; Neoplasms, Multiple Primary - genetics ; Organ Sites and Tumor Types ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Skin Neoplasms - epidemiology ; Skin Neoplasms - genetics ; Tropical medicine ; Tumors ; Tumors of the skin and soft tissue. Premalignant lesions ; United States - epidemiology</subject><ispartof>Cancer epidemiology, biomarkers &amp; prevention, 2006-08, Vol.15 (8), p.1520-1525</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</citedby><cites>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18036945$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16896043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BERWICK, Marianne</creatorcontrib><creatorcontrib>ORLOW, Irene</creatorcontrib><creatorcontrib>GALLAGHER, Richard P</creatorcontrib><creatorcontrib>DWYER, Terence</creatorcontrib><creatorcontrib>REBBECK, Timothy R</creatorcontrib><creatorcontrib>KANETSKY, Peter A</creatorcontrib><creatorcontrib>BUSAM, Klaus</creatorcontrib><creatorcontrib>FROM, Lynn</creatorcontrib><creatorcontrib>MUJUMDAR, Urvi</creatorcontrib><creatorcontrib>WILCOX, Homer</creatorcontrib><creatorcontrib>BEGG, Colin B</creatorcontrib><creatorcontrib>HUMMER, Amanda J</creatorcontrib><creatorcontrib>ARMSTRONG, Bruce K</creatorcontrib><creatorcontrib>KRICKER, Anne</creatorcontrib><creatorcontrib>MARRETT, Loraine D</creatorcontrib><creatorcontrib>MILLIKAN, Robert C</creatorcontrib><creatorcontrib>GRUBER, Stephen B</creatorcontrib><creatorcontrib>ANTON-CULVER, Hoda</creatorcontrib><creatorcontrib>ZANETTI, Roberto</creatorcontrib><creatorcontrib>GEM Study Group</creatorcontrib><creatorcontrib>The GEM Study Group</creatorcontrib><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><title>Cancer epidemiology, biomarkers &amp; prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</description><subject>Aged</subject><subject>Australia - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Canada - epidemiology</subject><subject>Case-Control Studies</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - genetics</subject><subject>Dermatology</subject><subject>Exons - genetics</subject><subject>Female</subject><subject>Germ-Line Mutation</subject><subject>Humans</subject><subject>International Agencies</subject><subject>Introns - genetics</subject><subject>Italy - epidemiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - genetics</subject><subject>Middle Aged</subject><subject>Neoplasms, Multiple Primary - epidemiology</subject><subject>Neoplasms, Multiple Primary - genetics</subject><subject>Organ Sites and Tumor Types</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - genetics</subject><subject>Tropical medicine</subject><subject>Tumors</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>United States - epidemiology</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkcFy0zAQhjUMDC2FR4DRBYaLy8q2LJlbCKVkSCBTylmzkdaNwZaDZJfpG_DYKE2YnnZ39O0v6f8ZeyngXAip3wmQMqvrSp5frBcZVBnkCh6xUyELnSkl5ePU_2dO2LMYfwKAqqV8yk5EpesKyuKU_b3eEl8HusWOvCU-NHz-8cvXfMYvKfTZsvXEV9OIYzv4yNE7fkVdmm6JX7XxF2-GwOfp3NMwRb7Crr3x6Ee-SpQfenzPZ54v_EjB32tgx9fDburuh-wDRnL8-zi5u-fsSYNdpBfHesZ-fLq4nn_Olt8uF_PZMrOlUGOmN0o1KBxUjdCVa5wmSyWopiDlNqpEsjovsCgdAFpRC-1yh7pUBHmdCyjO2JuD7i4MvyeKo-nbaKnrDl8wlVZJOFcJlAfQhiHGQI3ZhbbHcGcEmH0EZm-v2dtrUgQGKrOPIO29Ol4wbXpyD1tHzxPw-ghgtNg1Ab1t4wOnoajqUibu7YHbtjfbP20gYxNJIVAkDHZrhDTpETKH4h_DSJ4O</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>BERWICK, Marianne</creator><creator>ORLOW, Irene</creator><creator>GALLAGHER, Richard P</creator><creator>DWYER, Terence</creator><creator>REBBECK, Timothy R</creator><creator>KANETSKY, Peter A</creator><creator>BUSAM, Klaus</creator><creator>FROM, Lynn</creator><creator>MUJUMDAR, Urvi</creator><creator>WILCOX, Homer</creator><creator>BEGG, Colin B</creator><creator>HUMMER, Amanda J</creator><creator>ARMSTRONG, Bruce K</creator><creator>KRICKER, Anne</creator><creator>MARRETT, Loraine D</creator><creator>MILLIKAN, Robert C</creator><creator>GRUBER, Stephen B</creator><creator>ANTON-CULVER, Hoda</creator><creator>ZANETTI, Roberto</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><author>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Australia - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Canada - epidemiology</topic><topic>Case-Control Studies</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - genetics</topic><topic>Dermatology</topic><topic>Exons - genetics</topic><topic>Female</topic><topic>Germ-Line Mutation</topic><topic>Humans</topic><topic>International Agencies</topic><topic>Introns - genetics</topic><topic>Italy - epidemiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - genetics</topic><topic>Middle Aged</topic><topic>Neoplasms, Multiple Primary - epidemiology</topic><topic>Neoplasms, Multiple Primary - genetics</topic><topic>Organ Sites and Tumor Types</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - genetics</topic><topic>Tropical medicine</topic><topic>Tumors</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BERWICK, Marianne</creatorcontrib><creatorcontrib>ORLOW, Irene</creatorcontrib><creatorcontrib>GALLAGHER, Richard P</creatorcontrib><creatorcontrib>DWYER, Terence</creatorcontrib><creatorcontrib>REBBECK, Timothy R</creatorcontrib><creatorcontrib>KANETSKY, Peter A</creatorcontrib><creatorcontrib>BUSAM, Klaus</creatorcontrib><creatorcontrib>FROM, Lynn</creatorcontrib><creatorcontrib>MUJUMDAR, Urvi</creatorcontrib><creatorcontrib>WILCOX, Homer</creatorcontrib><creatorcontrib>BEGG, Colin B</creatorcontrib><creatorcontrib>HUMMER, Amanda J</creatorcontrib><creatorcontrib>ARMSTRONG, Bruce K</creatorcontrib><creatorcontrib>KRICKER, Anne</creatorcontrib><creatorcontrib>MARRETT, Loraine D</creatorcontrib><creatorcontrib>MILLIKAN, Robert C</creatorcontrib><creatorcontrib>GRUBER, Stephen B</creatorcontrib><creatorcontrib>ANTON-CULVER, Hoda</creatorcontrib><creatorcontrib>ZANETTI, Roberto</creatorcontrib><creatorcontrib>GEM Study Group</creatorcontrib><creatorcontrib>The GEM Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BERWICK, Marianne</au><au>ORLOW, Irene</au><au>GALLAGHER, Richard P</au><au>DWYER, Terence</au><au>REBBECK, Timothy R</au><au>KANETSKY, Peter A</au><au>BUSAM, Klaus</au><au>FROM, Lynn</au><au>MUJUMDAR, Urvi</au><au>WILCOX, Homer</au><au>BEGG, Colin B</au><au>HUMMER, Amanda J</au><au>ARMSTRONG, Bruce K</au><au>KRICKER, Anne</au><au>MARRETT, Loraine D</au><au>MILLIKAN, Robert C</au><au>GRUBER, Stephen B</au><au>ANTON-CULVER, Hoda</au><au>ZANETTI, Roberto</au><aucorp>GEM Study Group</aucorp><aucorp>The GEM Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</atitle><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>15</volume><issue>8</issue><spage>1520</spage><epage>1525</epage><pages>1520-1525</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><abstract>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16896043</pmid><doi>10.1158/1055-9965.EPI-06-0270</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1055-9965
ispartof Cancer epidemiology, biomarkers & prevention, 2006-08, Vol.15 (8), p.1520-1525
issn 1055-9965
1538-7755
language eng
recordid cdi_proquest_miscellaneous_68718627
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Aged
Australia - epidemiology
Biological and medical sciences
Canada - epidemiology
Case-Control Studies
Chromatography, High Pressure Liquid
Cyclin-Dependent Kinase Inhibitor p16 - genetics
Dermatology
Exons - genetics
Female
Germ-Line Mutation
Humans
International Agencies
Introns - genetics
Italy - epidemiology
Male
Medical sciences
Melanoma
Melanoma - epidemiology
Melanoma - genetics
Middle Aged
Neoplasms, Multiple Primary - epidemiology
Neoplasms, Multiple Primary - genetics
Organ Sites and Tumor Types
Polymerase Chain Reaction
Polymorphism, Genetic
Skin Neoplasms - epidemiology
Skin Neoplasms - genetics
Tropical medicine
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
United States - epidemiology
title The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A46%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Prevalence%20of%20CDKN2A%20Germ-Line%20Mutations%20and%20Relative%20Risk%20for%20Cutaneous%20Malignant%20Melanoma:%20An%20International%20Population-Based%20Study&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=BERWICK,%20Marianne&rft.aucorp=GEM%20Study%20Group&rft.date=2006-08-01&rft.volume=15&rft.issue=8&rft.spage=1520&rft.epage=1525&rft.pages=1520-1525&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/10.1158/1055-9965.EPI-06-0270&rft_dat=%3Cproquest_cross%3E68718627%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68718627&rft_id=info:pmid/16896043&rfr_iscdi=true